Roth Capital analyst Jotin Marango maintained a Buy rating on Actinium Pharmaceuticals (ATNM) today and set a price target of $6. The company’s shares closed yesterday at $0.60.
Marango noted:
“We believe that the likelihood of a study win (potentially as early as at interim next year) and, in turn, the derivative value of Iomab-B may be underappreciated by the Street. Context. (a) Iomab-B (anti-CD45 + Iodine-131) does not treat AML, but facilitates BMT which is the only curative intervention in AML. (b) The ongoing Phase 3 SIERRA study has a simple surrogate primary endpoint (CR durable at 180 days; dCR). (c) BMT conditioning is virgin territory, and Iomab-B is in pivotal stage with no close competitors. (d) In our view, there is opportunity to build value beyond AML upon study win, by expanding laterally into BMT conditioning across hem/onc.”
According to TipRanks.com, Marango is a 1-star analyst with an average return of -1.3% and a 28.3% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $4 average price target, a 564.0% upside from current levels. In a report issued on October 26, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $0.87 and a one-year low of $0.33. Currently, Actinium Pharmaceuticals has an average volume of 970.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Actinium Pharmaceuticals, Inc. engages in the development of targeted therapies for patients with cancers lacking effective treatment options. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells.
